Acamprosate calcium 333 MG Delayed Release Oral Tablet Campral

1 INDICATIONS AND USAGE Campral® is indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation. Treatment with Campral should be part of a comprehensive management program that includes psychosocial support. The efficacy of Campral in promoting abstinence has not been demonstrated in subjects who have not undergone detoxification and not achieved alcohol abstinence prior to beginning Campral treatment. The efficacy of Campral in promoting abstinence from alcohol in polysubstance abusers has not been adequately assessed. Campral® is indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation ( 1 , 14 ). Treatment with Campral should be part of a comprehensive management program that includes psychosocial support ( 1 ).

Forest Laboratories, Inc.

FDA Reported Adverse Reactions
[1] drug ineffective    [2] nausea    [3] fatigue    [4] headache    [5] toxicity to various agents    [6] pain    [7] off label use    [8] dyspnoea    [9] diarrhoea    [10] dizziness